| Giving full measure to countermeasures: addressing problems in the DoD program to develop medical countermeasures against biological warfare agents LZ Benet, JS Durch, LM Joellenbeck National Academies Press, 2004 | 3865* | 2004 |
| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3514 | 2010 |
| Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system CY Wu, LZ Benet Pharmaceutical research 22, 11-23, 2005 | 1703 | 2005 |
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: implications for drug delivery and activity in cancer chemotherapy VJ Wacher, CY Wu, LZ Benet Molecular carcinogenesis 13 (3), 129-134, 1995 | 1097 | 1995 |
| Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination LZ Benet, D Kroetz, L Sheiner, J Hardman, L Limbird Goodman and Gilman’s the pharmacological basis of therapeutics 3, e27, 1996 | 1014 | 1996 |
| Goodman & Gilman´ s. The Pharmacological Basic of Therapeutics LL Brunton Biblioteca Hernán Malo González, 2011 | 974* | 2011 |
| Clearance concepts in pharmacokinetics M Rowland, LZ Benet, GG Graham Journal of pharmacokinetics and biopharmaceutics 1 (2), 123-136, 1973 | 958 | 1973 |
| Noncompartmental determination of the steady‐state volume of distribution LZ Benet, RL Galeazzi Journal of pharmaceutical sciences 68 (8), 1071-1074, 1979 | 912 | 1979 |
| Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine KS Lown, RR Mayo, AB Leichtman, H Hsiao, DK Turgeon, ... Clinical pharmacology & therapeutics 62 (3), 248-260, 1997 | 879 | 1997 |
| BDDCS, the Rule of 5 and drugability LZ Benet, CM Hosey, O Ursu, TI Oprea Advanced drug delivery reviews 101, 89-98, 2016 | 774 | 2016 |
| The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein Y Zhang, LZ Benet Clinical pharmacokinetics 40, 159-168, 2001 | 702 | 2001 |
| BDDCS applied to over 900 drugs LZ Benet, F Broccatelli, TI Oprea The AAPS journal 13, 519-547, 2011 | 701 | 2011 |
| Gender effects in pharmacokinetics and pharmacodynamics RZ Harris, LZ Benet, JB Schwartz Drugs 50, 222-239, 1995 | 656 | 1995 |
| Role of P‐glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics VJ Wacher, JA Silverman, Y Zhang, LZ Benet Journal of pharmaceutical sciences 87 (11), 1322-1330, 1998 | 599 | 1998 |
| Design and optimization of dosage regimens; pharmacokinetic data LZ Benet The pharmacological basis of therapeutics 9/e, 1996 | 571* | 1996 |
| Acyl glucuronides revisited: is the glucuronidation proces a toxification as well as a detoxification mechanism? HS Langguth, LZ Benet Drug metabolism reviews 24 (1), 5-47, 1992 | 540 | 1992 |
| Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption JM Custodio, CY Wu, LZ Benet Advanced drug delivery reviews 60 (6), 717-733, 2008 | 527 | 2008 |
| The role of transporters in the pharmacokinetics of orally administered drugs S Shugarts, LZ Benet Pharmaceutical research 26, 2039-2054, 2009 | 499 | 2009 |
| Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction MF Hebert, JP Roberts, T Prueksaritanont, LZ Benet Clinical Pharmacology & Therapeutics 52 (5), 453-457, 1992 | 449 | 1992 |
| Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: studies with cyclosporine CY Wu, LZ Benet, MF Hebert, SK Gupta, M Rowland, DY Gomez, ... Clinical Pharmacology & Therapeutics 58 (5), 492-497, 1995 | 431 | 1995 |
